Takeda Completes Acquisition of URL Pharma - - BioPharm International

ADVERTISEMENT

Takeda Completes Acquisition of URL Pharma



Takeda Pharmaceutical Company Limited and its wholly owned subsidiary, Takeda Pharmaceuticals USA, jointly announced that the acquisition of URL Pharma for an upfront payment of $800 million has been completed. The deal also includes an agreement for future performance-based payments.

Takeda will immediately assume responsibility for the marketing and promotion of Colcrys (colchicine), URL Pharma’s leading product, which is used for the treatment and prevention of flares associated with gout. The addition of Colcrys to the company’s portfolio complements Takeda’s position in the gout marketplace with Uloric (febuxostat), used to lower blood uric acid levels in adults with gout. Douglas Cole, president of Takeda Pharmaceuticals USA said in the press release, “This commitment allows us to broaden our focus for patients by providing multiple therapeutic offerings for gout, which affects more than eight million Americans.”

The company expects that the acquisition will result in an immediate increase in revenue with estimated fiscal year 2012 net sales of more than $550 million and also expects continued growth of Colcrys sales throughout the product’s lifecycle.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here